These subtypes in most cases have specific immunological characteristics, differing in the quantity of tumor-infiltrating lymphocytes (TILs), programmed death ligand 1 (PD-L1) expression, and tumor-associated antigens, as well as the tumor mutational burden3–7. This evidence concerns the gene CD274 and neoplasm.